Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

SAGAsafe to feature in Servier clinical trials
April 2020
SHARING OPTIONS:

LUND, Sweden—SAGA Diagnostics AB has extended their collaboration with Servier, having established new service agreements that will run approximately two years. The partners will work together on three preclinical/clinical studies for which SAGA Diagnostics will develop assays and perform liquid biopsies on patients from Servier clinical studies using its SAGAsafe technology to identify and quantify circulating tumor DNA. Financial details for the collaboration were not released.
 
“We have been impressed by the service and ultra-sensitivity performance of SAGAsafe’s analyses and are looking forward to continue working together. Involving the SAGAsafe technology in these studies means that Servier will now be able to monitor effects at an earlier stage ensuring that we do not miss out on any insights,” remarked Brian Lockhart, director of CentEx-Biotechnology at Servier.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.